Company: CSTL
Filing Date: 2025-04-09
Form Type: DEF 14A
Source: 0001447362-25-000054
Chunk: 84

Company: CASTLE BIOSCIENCES INC
Filing Date: 2025-04-09
Form: DEF 14A
Chunk 84
---
 us to link compensation actually paid to our NEOs for the year-end December 31, 2024. For further information regarding these performance metrics and their function in our executive compensation program, please see “Compensation Discussion and Analysis” beginning on page 46.

| Performance Measures                |
| Financial Performance Measure:      |
| Revenue                             |
| Non-financial Performance Measures: |
| Reimbursement Rates for our Tests   |
| Pipeline Milestones                 |

All information provided above under the “Pay Versus Performance” heading will not be deemed to be incorporated by reference in any filing of our company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing, except to the extent the Company specifically incorporates such information by reference.

Policies and Practices Related to the Grant of Certain Equity Awards Close in Time to the Release of Material Nonpublic Information

During 2024 (and in the prior two years) we have not granted stock options, stock appreciation rights, or similar instruments with option-like features to our employees, including our named executive officers. From time to time, the Company may grant stock options to its non-employee members of the Board in circumstances where the Compensation Committee determines appropriate. The Company does not maintain any written policies on the timingof the grant of stock options, stock appreciation rights or similar instruments with option-like features.The Company has established written policies and practices on the timing of the grant of RSUs, which generally provide for preset grant dates.

It is our general policyto neither grant equity awards in anticipation of the release of material nonpublic information (“MNPI”), nor to timethe release of MNPI based on equity award grant dates or for the purposes of affecting the value of executive compensation.We have no information to disclose pursuant to Item 402(x)(2) of Regulation S-K.

#### Castle Biosciences 2025 Proxy Statement79
| Delinquent Section 16(a) Reports |

Section 16(a) of the Exchange Act requires our directors and executive officers, and persons who own more than ten percent of our common stock, to file with the SEC initial reports of ownership and reports of changes in beneficial ownership of our common stock.

Based on a review of Form 3 and Form 4 filings with the SEC and representations received from our current directors and executive officers that no Form 5 filings are required, we believe that all Section 16(a